Adults with treatment-resistant major depression who received intravenous ketamine twice a week for three weeks improved at rates statistically comparable to those who underwent electroconvulsive therapy, or ECT, three times a week over the same period. The finding comes from the ELEKT-D trial, an open-label, randomized, noninferiority study conducted across five U.S. ECT referral clinics. The results carry direct weight for the millions of Americans whose depression has not responded to standard antidepressants, because ketamine produced fewer cognitive side effects than ECT while matching its ability to reduce symptoms.
Why a head-to-head ketamine and ECT trial changes the clinical calculus
ECT has been the standard last-resort treatment for severe depression for decades, but its reputation for causing memory disruption has kept many patients and clinicians from choosing it. Ketamine, by contrast, acts through a different biological pathway, targeting glutamate signaling rather than inducing a seizure. That mechanistic difference matters most for patients whose depression centers on an inability to feel pleasure, a symptom known as anhedonia, because glutamate-driven changes in the brain’s reward circuits may address that deficit more directly than the broad neurochemical reset of a seizure. A peer-reviewed editorial published alongside the trial noted that ECT’s cognitive risks, particularly memory disruption, contrast with ketamine’s more common but transient side effects of dissociation and blood-pressure spikes.
The practical tension is straightforward. Hospitals have limited ECT capacity, and patients who qualify for it often delay or refuse treatment because of fears about memory loss. If ketamine performs just as well with a different and, for many patients, more tolerable side-effect profile, the risk-benefit conversation shifts. Clinicians can now point to a rigorous trial rather than relying on smaller, less definitive studies.
One hypothesis worth tracking in future research is whether patients with prominent anhedonia gain more sustained benefit from ketamine than from ECT. Because ketamine’s glutamatergic mechanism acts more directly on reward-circuit plasticity, those patients may represent a subgroup where the drug’s advantage is most pronounced. The ELEKT-D data have already generated secondary analyses exploring which patient characteristics predict better outcomes with one treatment or the other, though the acute three-week study window limits what can be said about long-term durability.
What the ELEKT-D trial measured and found
The trial, registered at ClinicalTrials.gov as NCT03113968, enrolled adults with nonpsychotic treatment-resistant major depression at five U.S. clinics. Participants were randomized to receive either IV ketamine at 0.5 mg/kg infused over 40 minutes twice weekly for three weeks, or ECT administered three times weekly for three weeks. The study used an open-label design, meaning both patients and clinicians knew which treatment was being given, and the primary question was whether ketamine was noninferior to ECT in reducing depression severity.
Response rates for ketamine met the noninferiority threshold. The trial’s design as a comparative-effectiveness study, rather than a traditional superiority trial, reflects the clinical reality that ECT already works well for many patients. The goal was not to prove ketamine is better but to establish that it is a viable alternative with a different side-effect trade-off. Earlier meta-analyses of smaller, more heterogeneous studies had pointed in the same direction, showing comparable symptom reduction between the two treatments but with enough variability to leave the question open. A systematic review and meta-analysis published before the ELEKT-D results synthesized the available comparative evidence but flagged small sample sizes and inconsistent study designs as significant limitations, underscoring the need for a larger, pragmatic trial.
A secondary analysis of the ELEKT-D data examined subgroup effects, adherence patterns, and safety details beyond the primary endpoint. That analysis, published in JAMA Network Open, found that ketamine adherence edged higher in certain patient subgroups, suggesting the drug’s twice-weekly infusion schedule and milder cognitive burden may make it easier for some patients to complete a full course of treatment. The secondary report helps clarify for whom ketamine or ECT may be more or less suitable, though it draws from the same three-week acute-phase data and cannot speak to outcomes beyond that window.
Gaps in the evidence and what patients should watch for next
The most significant limitation of the ELEKT-D trial is its three-week treatment window. Depression is a chronic, recurring condition, and knowing that ketamine works as well as ECT over 21 days does not answer whether that benefit holds at three months, six months, or a year. ECT has decades of follow-up data showing that many patients relapse without maintenance sessions. Ketamine’s long-term trajectory is far less established, and neither the primary trial report nor the secondary analysis includes detailed cognitive outcome data beyond the acute phase.
The open-label design introduces another wrinkle. Because patients knew which treatment they were receiving, expectations could have influenced how they reported symptom changes. Some may have entered the trial with strong preferences, either hoping to avoid ECT because of fear of memory problems or, conversely, believing ECT to be more powerful. While randomization helps balance these expectations across groups, it cannot fully eliminate placebo and nocebo effects in an unblinded study. That means the apparent equivalence between ketamine and ECT should be interpreted with an understanding that perception and stigma may have shaped some of the reported outcomes.
There are also unanswered questions about how best to maintain gains after the initial three-week course. In routine practice, ECT is often followed by a tapering schedule and then maintenance treatments spaced weeks or months apart. Ketamine, by contrast, has typically been delivered in short series of infusions, with some clinics offering periodic “booster” sessions, but there is no universally accepted maintenance protocol. The ELEKT-D trial did not directly compare long-term strategies, leaving clinicians to extrapolate from short-term data when deciding how to sustain improvement.
Safety profiles over longer horizons remain another gap. Acute side effects of ketamine, such as transient dissociation and elevated blood pressure, were well characterized in the trial, and serious adverse events were uncommon. Yet concerns about potential bladder problems, cardiovascular strain, and misuse with repeated exposure have not been fully resolved in treatment-resistant depression populations. ECT, for its part, carries anesthesia risks and short-term cognitive effects that are better documented but still vary widely by individual. Without head-to-head data extending beyond the acute phase, patients and clinicians must weigh a more established but invasive intervention against a newer option with promising efficacy but less long-term surveillance.
For patients considering these treatments now, the ELEKT-D findings change the starting point of the conversation. Instead of framing ECT as the only evidence-backed option when multiple antidepressants have failed, clinicians can present ketamine as a comparably effective alternative over the first few weeks, with a distinct side-effect profile and procedural burden. People who are especially concerned about memory, or who cannot easily commit to thrice-weekly hospital visits, may find ketamine’s schedule and cognitive profile more acceptable. Others, particularly those who have done well with ECT in the past, may still prefer the more established therapy.
Ultimately, the trial underscores the importance of individualized decision-making in severe, treatment-resistant depression. The choice between ketamine and ECT will hinge on a mix of clinical factors-such as symptom pattern, medical comorbidities, and prior treatment history-and personal values, including tolerance for cognitive risk, willingness to undergo anesthesia, and comfort with a newer drug-based approach. As longer-term and more finely stratified data emerge, the hope is that clinicians can move beyond broad equivalence and identify which patients are most likely to thrive with each intervention. Until then, ELEKT-D offers a crucial, if still partial, roadmap: for many adults facing some of the hardest-to-treat forms of depression, ketamine is no longer an experimental outsider but a legitimate peer to ECT in the early phase of care.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
